Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Classifica tra le azioni #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prezzo delle azioni
$208.57
Capitalizzazione di mercato
$368.78B
Variazione (1 giorno)
0.68%
Variazione (1 anno)
3.61%
Paese
US
Scambia AbbVie Inc. (ABBV)

Categoria

Rapporto P/B per AbbVie Inc. (ABBV)
Rapporto P/B al March 2026 TTM: -119.61
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di AbbVie Inc., il rapporto P/B attuale (TTM) è -119.61. Alla fine del 2024, era pari a 94.54.
Storico del rapporto P/B per AbbVie Inc. da 2009 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) -119.61 -100.00%
2025 0.00 -100.00%
2024 94.54 257.48%
2023 26.45 59.43%
2022 16.59 6.65%
2021 15.55 13.87%
2020 13.66 -185.13%
2019 -16.05 -4.60%
2018 -16.82 -155.55%
2017 30.28 38.22%
2016 21.91 -10.22%
2015 24.40 -59.27%
2014 59.92 220.74%
2013 18.68 16.62%
2012 16.02 237.93%
2011 4.74 31.60%
2010 3.60 0.00%
2009 0.00 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
33.3372 -127.87%
US
6.0657 -105.07%
GB
7.1931 -106.01%
US
6.3334 -105.30%
CH
5.4725 -104.58%
US